NWL 149 - New World Laboratories
Alternative Names: NWL-149 - New World LaboratoriesLatest Information Update: 06 Nov 2023
At a glance
- Originator New World Laboratories
- Class Antidementias; Cardiovascular therapies; Peptidomimetics
- Mechanism of Action Caspase 1 modulators; Caspase 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Cardiovascular disorders; Multiple sclerosis
Most Recent Events
- 26 Sep 2023 Preclinical trials in Alzheimer's disease in Canada (unspecified route), September 2023 (New World Laboratories pipeline, September 2023)
- 26 Sep 2023 Preclinical trials in Cardiovascular disorders in Canada (unspecified route), September 2023 (New World Laboratories pipeline, September 2023)
- 26 Sep 2023 Preclinical trials in Multiple sclerosis in Canada (unspecified route), September 2023 (New World Laboratories pipeline, September 2023)